Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25622840 | 0.88 | — | — | |
| SCHEMBL25622841 | 0.88 | — | — | |
| SCHEMBL16409833 | 0.88 | — | — | |
| SCHEMBL18838426 | 0.84 | TSHR (0.31) | TSHRSMN1; SMN2 | |
| SCHEMBL2376071 | 0.75 | TSHR (0.37) | TXNRD1TSHRSMN1; SMN2 | |
| SCHEMBL14667090 | 0.74 | PIK3CD (0.33) | — | |
| SCHEMBL19881002 | 0.74 | TSHR (0.33) | TSHRSMN1; SMN2 | |
| SCHEMBL15695398 | 0.71 | TSHR (0.32) | TXNRD1TSHRSMN1; SMN2 | |
| SCHEMBL19544959 | 0.71 | HTR2A (0.35) | — | |
| SCHEMBL23239726 | 0.69 | PIK3CD (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167296-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATIONAL GMBH (DE) | 2019-01-01 | — | — | US | disclosed |
| US-20170260195-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2017-09-14 | — | — | US | disclosed |
| US-9708274-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATIONAL GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260195-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, PDXK, NEK2 | TXNRD1 495/4885CHEK1 130/4885MTOR 643/4885 |
| US-10167296-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | NEK5, PDXK, NEK2 | TXNRD1 462/4885CHEK1 140/4885MTOR 656/4885 |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, NEK2, SIK2 | TXNRD1 464/4885CHEK1 148/4885MTOR 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.